Journals / Göztepe Tıp Dergisi / 2012 / Cilt: 27 - Sayı: 4

Rapid treatment with electroconvulsive therapy in a patient with mental retardation who developed neuroleptic malignant syndrome

Nöroleptik malign sendrom gelişen mental retarde bir hastanın elektrokonvülsif tedavi ile hızlı sağaltımı

Pages
185–187
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report, the clinical course and positive response to ECT of a male patient with mental retardation who developed NMS, after implementation of the fluphenazine decanoate was examined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic adverse reaction which occurs after use of antipsychotic drugs that block dopamine.
📊
Key Findings & Data:Patients with mental retardation are at high risk for the development of NMS espe- cially at high dose, first time, and intramuscular usage of neuroleptic medication.
💡
Conclusion & Impact:In this case report, the clinical course and positive response to ECT of a male patient with mental retardation who developed NMS, after implementation of the fluphenazine decanoate was examined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic adverse reaction which occurs after use of antipsychotic drugs that block dopamine. Patients with mental retardation are at high risk for the development of NMS espe- cially at high dose, first time, and intramuscular usage of neuroleptic medication. In this case report, the clinical course and positive response to ECT of a male patient with mental retardation who developed NMS, after implementation of the fluphenazine decanoate was examined.

Özet

Nöroleptik malign sendrom (NMS) hayati tehlike oluşturan idiyosinkratik, istenmeyen bir etki olup, dopamin blokajı yapan antipsikotik ilaç kullanımı sonrası ortaya çıkmaktadır. Yüksek doz, ilk kez ve özellikle kas içi nöroleptik kullanan mental retardasyonlu hastalar NMS gelişimi için daha yüksekrisk altındadır. Bu olgu sunumunda mental retardasyonu olan bir erkek hastada, flufenazin dekanoat uygulanması sonrasıgelişen NMS, klinik seyri ve elektrokonvulsif tedavi (EKT) olumlu yanıtı incelenmiştir.

🔖

Cite This Article

BAYAZIT, H., KARABABA, İ. F., POYRAZ, E. (2022). Rapid treatment with electroconvulsive therapy in a patient with mental retardation who developed neuroleptic malignant syndrome. Göztepe Tıp Dergisi, Cilt: 27 - Sayı: 4, 185–187. https://ajindex.com/articles/526099

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999
  2. 33(5):650-9. Review. PubMed PMID: 10544988 2. Orhan O, Zencirci B, Oksuz H ve ark. Noroleptik malign sendrom: Tedaviye sertralin eklenmesi sonrası ortaya çıkan bir olgunun sunumu. Klinik Psikofarmakoloji Bulteni 2007
  3. Doğan N, Kurflad H, Erdem AF, Kızılkaya M. Noroleptik malign sendromda nadir etyolojik faktorler ve klinik seyir. AUTD 2003
  4. Aruna AS, Murungi JH. Fluphenazine-induced neuro- leptic malignant syndrome in a schizophrenic patient. Ann Pharmacother 2005
  5. http://dx.doi.org/10.1345/aph.1E492 PMid:15840734 5. Pelonero AL, Levenson JL, Pandurangi AK. Neurolep- tic malignant syndrome: a review. Psychiatr Serv 1998
  6. PMid:9735957 6. Akdeniz F, Noyan MA. Elektrokonvülsif tedavinin diğer endikasyonları. Ege Psikiyatri Dergisi 1998
  7. Viejo LF, Morales V, Punal P, Perez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case- control study. Acta Psychiatr Scand 2003
  8. http://dx.doi.org/10.1034/j.1600-0447.2003.02385.x PMid:12558541 8. Rasmussen KG. Risk factors for neuroleptic malignant syndrome. Am J Psychiatry 1998
  9. PMid:9812150 9. Shalev A, Hermesh H, Munitz H. Mortality from neurolep- tic malignant syndrome. J Clin Psychiatry 1989
  10. PMid:2562951 10. Ozer F, Meral H, Aydin B, Hanoglu L, Aydemir T, Oral T. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005
  11. 21(2):125-7. http://dx.doi.org/10.1097/01.yct.0000159325.08303.45 PMid:15905757 11. Tomruk NB, Kutlar MT, Mengeş OO, Canbek Ö, Soysal H. Elektrokonvulsif Tedavi Klinik Uygulama El Kitabı, 2007, 59.